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Background: We aimed to assess the hospital economic costs of nosocomial multi-drug resistant Pseudomonas
aeruginosa acquisition.
Methods: A retrospective study of all hospital admissions between January 1, 2005, and December 31, 2006 was
carried out in a 420-bed, urban, tertiary-care teaching hospital in Barcelona (Spain). All patients with a first positive
clinical culture for P. aeruginosa more than 48 h after admission were included. Patient and hospitalization
characteristics were collected from hospital and microbiology laboratory computerized records. According to
antibiotic susceptibility, isolates were classified as non-resistant, resistant and multi-drug resistant. Cost estimation
was based on a full-costing cost accounting system and on the criteria of clinical Activity-Based Costing methods.
Multivariate analyses were performed using generalized linear models of log-transformed costs.
Results: Cost estimations were available for 402 nosocomial incident P. aeruginosa positive cultures. Their
distribution by antibiotic susceptibility pattern was 37.1% non-resistant, 29.6% resistant and 33.3% multi-drug
resistant. The total mean economic cost per admission of patients with multi-drug resistant P. aeruginosa
strains was higher than that for non-resistant strains (15,265 vs. 4,933 Euros). In multivariate analysis, resistant and
multi-drug resistant strains were independently predictive of an increased hospital total cost in compared with
non-resistant strains (the incremental increase in total hospital cost was more than 1.37-fold and 1.77-fold that for
non-resistant strains, respectively).
Conclusions: P. aeruginosa multi-drug resistance independently predicted higher hospital costs with a more than
70% increase per admission compared with non-resistant strains. Prevention of the nosocomial emergence and
spread of antimicrobial resistant microorganisms is essential to limit the strong economic impact.
Keywords: Antimicrobial resistance, Economic analysis, Hospital cost, Multi-drug resistance, Pseudomonas
aeruginosaBackground
Antibiotic resistance is a growing clinical problem and a
major public health threat. Infections caused by anti-
biotic resistant microorganisms usually result in signifi-
cantly higher morbidity, longer hospitalization, increased
mortality rates, and excess health care costs compared
with antibiotic-susceptible microorganisms [1,2]. Although
much attention has focused on emerging antibiotic-
resistant Gram-positive bacteria such as methicillin-* Correspondence: FCots@parcdesalutmar.cat
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reproduction in any medium, provided the orresistant Staphylococcus aureus and vancomycin-resistant
Enterococcus, resistance within Gram-negative bacilli con-
tinues to rise [3], occasionally creating situations in which
few or no antibiotics that retain activity are available.
Pseudomonas aeruginosa is a Gram-negative bacterial
pathogen that causes severe nosocomial infections [4].
This microorganism is a leading cause of nosocomial
infections and is responsible for 10% of all hospital-
acquired infections, ranking second among Gram-negative
pathogens [5,6]. Multi-drug resistance to antipseudomonal
antibiotics is a common and increasing problem in some
hospitals [7,8]. Infections by multi-drug resistant P. aerugi-
nosa (MDRPA) are associated with increased morbidity
[9], mortality [7,10], and economic impact [11]. A numberl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Morales et al. BMC Health Services Research 2012, 12:122 Page 2 of 8
http://www.biomedcentral.com/1472-6963/12/122of studies have evaluated the impact of P. aeruginosa
antibiotic resistance through assessment of in-hospital
mortality rates and length of hospitalization [7-11]. How-
ever, fewer studies have quantitatively examined in detail
the hospital economic impact of MDRPA infections and
most have been limited to case series studies and out-
breaks [11,12].
Not only morbidity and mortality, but also the eco-
nomic cost may be a sensitive measure to quantify the
burden of antimicrobial resistance [13]. In addition, esti-
mating cost outcomes due to antimicrobial resistance
may be useful to prompt hospitals and health care provi-
ders to introduce and support initiatives to prevent such
infections, to influence health care providers to follow
isolation guidelines, and to make appropriate use of anti-
biotics. Moreover, data can guide policy makers who take
decisions on the funding of programs to track and pre-
vent the spread of antimicrobial-resistant microorganisms.
The objective of this study was to assess the hospital
economic costs of MDRPA acquisition in a tertiary hos-
pital in Barcelona (Spain) during the period 2005–2006.
Methods
Study design and setting
A retrospective study was performed at Hospital del
Mar, a 420-bed, urban, tertiary-care teaching hospital
that covers an area of 300,000 inhabitants in the city of
Barcelona, Catalonia (Spain). The study was carried out
in compliance with the Helsinki Declaration. The study
was approved by the ethics committee of IMIM-Hospital
del Mar.
The study population consisted of all hospital admis-
sions between January 1, 2005 and December 31, 2006
in which a nosocomial incident P. aeruginosa was iso-
lated and identified. We used the microbiology labora-
tory records of the hospital to identify all inpatients with
positive clinical cultures for P. aeruginosa. Clinical speci-
mens were isolated and identified by the microbiology
laboratory by means of routine techniques. Nosocomial
incident P. aeruginosa acquisitions were defined as those
in which the first P. aeruginosa positive culture for a
particular patient occurred more than 48 h after patient
admission during the study period. Overall, 410 incident
nosocomial P. aeruginosa positive cultures were identi-
fied. The present report is based on 402 admissions with
complete information on antibiotic susceptibility pattern
and economical cost estimations (98% of the 410 posi-
tive cultures).
The susceptibility of isolates was determined by two
methods: the MicroScan Walk away (Siemens Health-
care) (using NC36 and NC38 panels) or the Kirby Bauer
method in Muller Hinton plates (Biomerieux Marcy
l’etoile). Antibiotic susceptibility tests were performed using
a standardized custom microtiter minimum inhibitoryconcentration (MIC). Testing procedures were validated
by determining the MICs for reference strains. P. aerugi-
nosa isolates were classified in three categories according
to the antibiotic susceptibility pattern to all studied agents
as: 1) non-resistant P. aeruginosa when the organism
was susceptible to all the agents studied; 2) multi-drug
resistant (MDRPA) for strains resistant to carbapenems,
b-lactams, quinolones, tobramycin, and gentamicin and
sensitive to colistin and amikacin [5,8,14]; and 3) resistant
P. aeruginosa all the possible remainder combinations.
This information was linked to a hospital computer-
ized patient records database. The following information
was retrieved for each admission during the study
period: patient age and sex, cause of hospitalization,
medical treatments and comorbidities, previous hospita-
lization in the same hospital, previous intensive care unit
(ICU) stay during the same hospital admission, exposure
to invasive devices or procedures (mechanical ventila-
tion, hemodialysis, bronchoscopy, digestive endoscopy
and surgery); length of hospital stay (LOS) (including
the LOS before detection defined as the period of
time from admission to microorganism detection; and
total LOS defined as the period of time from admission
to the discharge or death of the patient), previous anti-
biotic therapy during the current hospitalization episode,
and in-hospital mortality. Moreover, underlying illness
severity was measured by the All Patient Refined Diag-
nosis Related Group Severity of Illness scale (version
20.0) [15].
Costs estimation
The Municipal Institute of Health uses a hospital cost
accounting system based on full-costing allocation
that allows for assessing direct cost derived from clinical
activity [16]. In the present study, cost estimation was
based on a full-costing cost accounting system and on
the criteria of clinical Activity-Based Costing (ABC)
methods to obtain the highest sensitivity in the assess-
ment of variability in clinical activity. Moreover, this
system ensures that the hospital’s total costs are distribu-
ted among the patients. Allocation was based on directly
assigning the cost of the following services to the
patient: laboratory, pharmacy, radiology, nuclear medi-
cine, pathology, and prosthetics [17,18]. The information
systems contain exhaustive data on human resources
and their activity: storage, admissions planning, ambula-
tory and emergency care, operating rooms, diagnostic
and complementary tests, and inter-hospital consulta-
tions. This information creates and automatically updates
the cost drivers for overheads [19,20].
The principal economic outcome assessed was total
hospital cost of nosocomial MDRPA acquisition. To
avoid the overestimation effect of costs due to extra
LOS, all hospital costs were estimated once a positive
Table 1 Principal characteristics for hospital admission according to the antibiotic susceptibility pattern of nosocomial
Pseudomonas aeruginosa (PA) isolates. Barcelona (Spain), 2005–2006 (n =402)
Non-resistant PA Resistant PA Multi-drug resistant PA P *
N = 149 (37.1%) N=119 (29.6%) N=134 (33.3%)
YEAR
2005 77 (51.7) 60 (50.4) 78 (58.2) 0.402
2006 72 (48.3) 59 (49.6) 56 (41.8)
PATIENT VARIABLES
Male sex, n (%) 87 (58.4) 80 (67.2) 100 (74.6) 0.015
Age, years
Mean (sd) 68.6 (17.0) 67.4 (17.0) 67.4 (13.7) 0.348**
Median 71.0 73.0 70.5
Clinical conditions, n (%)
Chronic obstructive pulmonary disease 33 (22.1) 30 (25.2) 40 (29.9) 0.332
Solid neoplasia 41 (27.5) 25 (21.0) 27 (20.1) 0.289
Diabetes mellitus 26 (17.4) 28 (23.5) 23 (17.2) 0.364
Renal disease 15 (10.1) 5 (4.2) 19 (14.2) 0.021
Liver disease 10 (6.7) 10 (8.4) 17 (12.7) 0.216
HIV infection 6 (4.0) 4 (3.4) 4 (3.0) 0.942
Hematological neoplasia 5 (3.4) 4 (3.4) 4 (3.0) 1.000
Chemotherapy 1 (0.7) 1 (0.8) 3 (2.2) 0.531
Source of infection
Respiratory 64 (42.9) 57 (47.9) 63 (47.0) 0.677
Skin & soft tissue 41 (27.5) 32 (26.9) 23 (17.2) 0.076
Genitourinary 26 (17.5) 15 (12.6) 27 (20.2) 0.275
Catheter 7 (4.7) 3 (2.5) 9 (6.7) 0.306
Endovascular 2 (1.3) 7 (5.9) 7 (5.2) 0.099
Abscess 3 (2.0) 5 (4.2) 1 (0.8) 0.184
Peritonitis 3 (2.0) 0 (0.0) 2 (1.5) 0.386
Digestive 2 (1.3) 0 (0.0) 1 (0.8) 0.779
Others 1 (0.7) 0 (0.0) 1 (0.8) 1.000
Underlying illness severity score
1-3 112 (77.8) 62 (56.9) 68 (53.5) <0.001
4 32 (22.1) 47 (41.2) 59 (45.0)
HOSPITALIZATION VARIABLES
Previous hospitalization, n (%)
None 68 (45.6) 39 (32.8) 42 (31.3) 0.068
1 28 (18.8) 22 (18.5) 21 (15.7)
2 20 (13.4) 20 (16.8) 20 (14.9)
>= 3 33 (22.1) 38 (31.9) 51 (38.1)
Invasive devices or procedures, n (%)
Mechanical ventilation 9 (6.0) 29 (24.4) 31 (23.1) <0.001
Hemodialisys 0 (0.0) 2 (1.7) 8 (6.0) 0.002
Bronchoscopy 13 (8.7) 12 (10.1) 23 (17.2) 0.080
Digestive endoscopy 12 (8.1) 6 (5.0) 12 (9.0) 0.479
Surgery 91 (61.1) 74 (62.2) 80 (59.7) 0.917
Previous ICU stay (yes), n (%) 18 (12.1) 40 (33.6) 34 (25.4) <0.001
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Table 1 Principal characteristics for hospital admission according to the antibiotic susceptibility pattern of nosocomial
Pseudomonas aeruginosa (PA) isolates. Barcelona (Spain), 2005–2006 (n =402) (Continued)
LOS before detection, days
Mean (sd) 12.9 (10.0) 17.9 (15.5) 21.9 (14.9) <0.001**
Median 10.0 14.0 18.0
Total LOS, days
Mean (sd) 25.1 (16.1) 39.0 (30.3) 45.7 (29.1) <0.001**
Median 20.0 30.0 39.0
Previous antibiotic therapy, n (%)
None 69 (46.3) 25 (21.0) 15 (11.2) <0.001
No anti-Pseudomonas aeruginosa drugs 60 (40.3) 40 (33.6) 25 (18.7)
Anti-Pseudomonas aeruginosa drugs 20 (13.4) 54 (45.4) 94 (70.1)
In-hospital mortality, n (%) 19 (12.8) 26 (21.8) 33 (24.6) 0.026
*Otherwise indicated p value derived form Fisher’s exact test. **p value derived from Kruskal Wallis test.
HIV: Human Immunodeficiency Virus; ICU: intensive care unit; LOS: length of hospital stay.
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cost and pharmacy cost. Fixed cost derived from surgical
procedures, hospitalization, and ICU stay, was distribu-
ted based on routine criteria: operation or intervention
time, or the number of days of stay among the various
hospitalization units. Variable cost included the costs
derived from laboratory, radiology, pathology, prostheses,
tests and pharmacy. In addition, we evaluated the effect
of nosocomial MDRPA acquisition on pharmacy cost.
Statistical analysis
Patient admission represented the unit of analysis. Uni-
variate statistics were computed as customary. In contin-
gency tables, Fisher's exact test for homogeneity or
independence was applied to assess the relationship
between two categorical variables; the Kruskal-Wallis
and Mann–Whitney U-tests were used to compare con-
tinuous variables. The main effects of all predictors were
independently explored in base models. Hospital costs
were log transformed to achieve a normal distribution as
far as possible. Multivariate analyses of hospital cost
were performed using generalized linear models with
the Gamma distribution and the log link function. The
coefficients were converted to the measures of effect
using an exponential transformation. Final multivariate
models were adjusted for patient age and sex, comorbid-
ities, average total cost per Diagnosis-Related-Groups
(DRG) of patients with the lowest severity score, source
of infection, stay (or not) in UCI after the infection and
in-hospital mortality. The level of statistical significance
was set at 0.05, and all tests were two tailed. Analyses
were conducted using PASW Statistics 18 version 18.0.0
(IBM corp., 2009).
Results
Overall, 402 incident P. aeruginosa positive cultures
among hospitalized patients were identified during thestudy period. Their distribution by antibiotic susceptibil-
ity pattern was 149 (37.1%) non-resistant, 119 (29.6%)
resistant, and 134 (33.3%) multi-drug resistant.
Table 1 shows the clinical characteristics of patients
and the hospitalization process according to the anti-
biotic susceptibility pattern of P. aeruginosa isolates. The
distribution of positive cultures differed between the
sexes, with 67.2% and 74.6% of patients infected with
resistant and multi-drug resistant PA, respectively, being
male compared with 58.4% of patients with a non-
resistant strain. The median age of patients was similar
among all antibiotic susceptibility pattern groups.
Patients with positive culture to resistant and multi-drug
resistant PA strains showed a higher underlying illness
severity score in comparison with those with non-
resistant strains (41.2% and 45.0%, respectively, vs.
22.1%). Patients with resistant and multidrug-resistant
PA strains were exposed in higher proportion to invasive
procedures/devices, such as mechanical ventilation,
hemodialysis, and bronchoscopy than patients with non-
resistant strains. Resistant and multi-drug resistant PA
strains were more prevalent among patients previously
admitted to the ICU. The mean LOS was longer among
patients with resistant (39.0 days) and multi-drug resist-
ant P. aeruginosa (45.7 days) strains than among those
with non-resistant strains (25.1 days). The use of previ-
ous anti-P. aeruginosa antibiotic therapy was more
common among patients with resistant (45.4%) and
multi-drug resistant P. aeruginosa (70.1%) isolates than
in those with non-resistant isolates (13.4%). In-hospital
mortality was significantly higher among patients with
resistant and multi-drug resistant PA strains than in
those with non-resistant strains (24.6% vs. 12.8%).
The care of patients with antibiotic MDRPA positive
cultures resulted in a significant higher median hospital
economic cost than those with non-resistant strains
(Table 2). The total mean economic cost per admission
Table 2 Economic costs (Euros) per hospital admission according to the antibiotic susceptibility pattern of nosocomial
Pseudomonas aeruginosa (PA) isolates. Barcelona (Spain), 2005–2006 (n =402)
Non-resistant PA Resistant PA Multi-drug resistant PA P *
N = 149 (37.1%) N=119 (29.6%) N=134 (33.3%)
Fixed cost
Mean (95% CI) 3,983 (3,168-4,797) 9,597 (7,184-12,009) 11,421 (8,858-13,983) <0.001
Median 2,194 (1,673-2,629) 4,844 (3,809-6,860) 5,079 (3,922-7,024)
Variable cost
Mean (95% CI) 950 (701–1,200) 2,754 (1,504-4,005) 3,844 (2,742-4,946) <0.001
Median 368 (250–523) 897 (670–1,502) 1,218 (812–1,867)
Pharmacy cost
Mean (95% CI) 473 (331–615) 1,964 (873–3,055) 2,781 (1,863-3,699) <0.001
Median 135 (83–182) 594 (423–765) 725 (481–1,096)
Total cost
Mean (95% CI) 4,933 (3,911-5,956) 12,351 (8,858-15,845) 15,265 (11,834-18,696) <0.001
Median 2,803 (2,026-3,431) 6,079 (4,829-8,049) 6,655 (4,771-10,200)
* p value derived from Kruskal Wallis test. CI: confidence interval.
Table 3 Variables predicting total economic cost of
nosocomial Pseudomonas aeruginosa isolates. Barcelona
(Spain), 2005–2006, (N= 402)
Independent variable Coefficient (95% CI) P
Antibiotic susceptibility pattern
Non-resistant 1.00
Resistant 1.37 (1.08-1.72) 0.009
Multi-drug resistant 1.77 (1.41-2.22) <0.001
Sex, male 1.12 (0.91-1.37) 0.277
Age 1.00 (0.98-1.00) 0.161
Source of infection
Respiratory 0.91 (0.67-1.22) 0.538
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fold in comparison with non-resistant strains (€15,265 vs.
€4,933). This increased economic cost of resistant and
multidrug-resistant P. aeruginosa strains was also
observed in pharmacy, variable and fixed costs. The high-
est increased cost was found for pharmacy cost which
was more than 6-fold higher in patients with MDRPA
positive cultures in comparison with admissions with
non-resistant strains (€2,781 vs. €473).
On multivariate analysis, resistant and multi-drug
resistant PA positive cultures were independently pre-
dictive of increased hospital total cost in comparison
with non-resistant strains (an incremental increase in
total hospital cost higher than 1.37-fold and 1.77-fold,
respectively) (Table 3). In addition, other predictive fac-
tors independently contributed toward increased total
hospital economic cost including ICU stay post infection
and average cost per DRG (Table 3). After adjusting for
potential confounders, the impact of MDRPA positive
cultures was much higher on pharmacy cost (a 3.25-fold
increase estimated with respect to non-resistant strains)
than on total cost (Table 4).Skin & soft tissue 0.85 (0.61-1.16) 0.311





Solid neoplasm 1.00 (0.79-1.24) 0.979
Diabetes mellitus 1.22 (0.96-1.55) 0.102
Renal disease 0.85 (0.61-1.16) 0.313
Liver disease 1.20 (0.87-1.65) 0.261
UCI stay post infection 3.46 (2.70-4.41) <0.001
Average total cost per DRG 1.43 (1.28-1.60) <0.001
In-hospital mortality 0.96 (0.75-1.21) 0.720Discussion
We assessed the hospital economic impact of nosoco-
mial MDRPA acquisition in a tertiary hospital. Our com-
parison group was composed of patients with positive
cultures admitted. Active surveillance of nosocomial
infections was not implemented in our centre, thus most
of the cases included in the present study corresponded
with infected patients. Therefore, the present results
should be interpreted as the impact of antibiotic resist-
ance on hospital costs. The mean hospital total cost per
admission was Є12,351 for patients who acquiredresistant and €15,265 for MDRPA strains, which was
substantially higher than the Є4,933 for those with non-
resistant strains. On multivariate analysis, we found an
independent contribution of P. aeruginosa multi-drug
resistance acquisition to increased total cost per hospital
admission, which was more than 1.7 fold higher in com-
parison with non-resistant microorganisms. Pharmacy
Table 4 Influence of antibiotic susceptibility pattern of
nosocomial Pseudomonas aeruginosa isolates on
pharmacy cost. Barcelona (Spain) 2005–2006, (N=402).
Coefficient (95% CI) P
Non-resistant 1.00
Resistant 2.15 (1.54-2.99) <0.001
Multi-drug resistant 3.25 (2.38-4.42) <0.001
Adjusted for sex, age, average total cost per Diagnosis–related-groups, source
of infection, clinical conditions, UCI stay post infection, and in-hospital
mortality.
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than 3-fold.
Antibiotic multi-resistant infections caused by Gram-
negative bacilli are emerging in hospital settings and are
becoming a major clinical and public health issue. Des-
pite of the absence of an international consensus on the
definition of multi-drug resistance in P. aeruginosa com-
plicating comparison between studies [21], we found a
higher prevalence of multi-drug resistance than previous
reports from the European Antimicrobial Resistance
Surveillance System (EARSS) Annual Report for 2006
[http://www.rivm.nl/earss/result/Monitoring_reports/], 18%
of P. aeruginosa isolates were found to be multidrug-
resistant, i.e. resistant to three or more antibiotics from
the EARSS protocol [5]. This change in trends strength-
ens the importance of assessing the impact of the in-
crease in multi-drug resistance on hospital outcomes not
only in terms of mortality or prolongation of hospital
stay, but also on economic costs.
Globally, it is estimated that infections due to
antimicrobial-resistant organisms have higher costs ran-
ging between $6,000 and $30,000 than do infections due
to antimicrobial susceptible organisms [13]. In our study,
the mean cost per hospital admission with a positive
culture of MDRPA was €15,265, which was substantially
higher than that of hospital admissions infected with
non-resistant strains (mean of €4,933). Previous studies
have estimated the hospital cost increase due to MDRPA
infections. In an ICU outbreak, Bou et al. [12] reported
that the emergence of antibiotic multi-resistance in
P. aeruginosa infections was significantly associated with
a high median economic cost (€72,356 vs €17,090;
P< 0.004). Lautenbach et al. [22] reported that patients
infected with imipenem-resistant Pseudomonas aerugi-
nosa had greater hospital costs (US$81,330 vs. US
$48,381; P< 0.001). In a matched cohort study Carmeli
et al. [9] estimated that emergence of resistance to
P. aeruginosa increased the total hospital charges by
$7,340. In a case-series study, Harris et al. [11] reported
that the mean cost of the admission during which the
first multi-resistant isolate of P. aeruginosa was cultured
was of $54,081, compared with a mean cost of $22,116
for patients infected with susceptible strains. Most ofthese studies were limited to case series and outbreaks
among patients in ICU, which may partly explain the dif-
ferences in cost estimations in comparison with current
estimations. Also the inclusion in our study of both
infections and colonizations could result in underesti-
mated costs. In addition, diverse cost estimation method-
ology could influence differences in cost estimations
when comparing studies.
When analyzing different types of hospital cost, we
found a remarkable increment in hospital cost due to
MDRPA strains in pharmacy cost. Although not exclu-
sively, pharmacy excess costs associated with multi-drug
resistant microorganisms may partly be due to delayed
appropriate antibiotic therapy and the need to use
more expensive antibiotics, which implies a substantial
increase in drug therapy cost. In our experience,
colistin (polimixin-E) is the first choice antimicrobial
for MDRPA infections [14]. Comparatively with other
antipseudomonals colistin is as expensive as other
broad- spectrum anti-pseudomonas antibiotics such as
carbapenems or the pip/tazo combination. Importantly,
these excess costs are potentially avoidable.
Notable among the strengths of the study is that infor-
mation was available from almost all P. aeruginosa
acquisitions detected among hospital admissions during
the study period. This study has some limitations. To
estimate the effect of antibiotic resistance on the eco-
nomic cost of nosocomial acquisitions, patients with
antibiotic resistant microorganisms were compared with
those without resistant organisms for hospital cost out-
comes. The problem with this simple comparison is that
sicker patients with longer length of hospital stay,
greater severity, and comorbidities are more likely to
acquire resistant organisms, leading to substantial con-
founding bias. However, we addressed this problem by
detailed adjustment to control as much as possible the
factors other than antibiotic resistance that contributed
to adverse outcomes, such as severity, and UCI stay post
infection. This enabled us to isolate the independent
effect of P. aeruginosa acquisition on hospital costs.
Another relevant limitation in estimating hospital cost in
relation to infection acquisition involves time and length
bias [23]. However, no statistical solution exists for mod-
els involving a quantitative dependent variable such as
cost, which cannot be directly related to time. Thus, to
address this methodological issue we used costs after
infection as dependent variable, which can reduce cost
overestimation due to time and length bias. On the
other hand, using generalized linear models (GLM) to
estimate hospital costs could result in biased and over-
estimated costs. However, a recent study comparing dif-
ferent analytic approaches did not demonstrate that
multistate methods are better than GLM or propensity
score adjustments [24]; and the most important issue
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using the real cost for each day of stay and for each pa-
tient and on the quality of the data [24]. Moreover, our
cost estimates most closely represent the direct hospital
perspective, which provides a partial view of the health
care impact of antibiotic resistance. Thus, we
believe that the hospital perspective is to some extend
also underestimated because we did not account for
extra costs to the institution at large attending patients
with MDRPA infections, such as surveillance cultures,
isolation supplies, and loss of beds due to the need to
isolate a patient. And in addition, the effects extending
beyond hospitalization were underestimated by this
study. Finally, data from one centre and one particular
health care system could limit broader applicability of
the present results.
Conclusions
In conclusion, MDRPA acquisition is becoming a serious
issue in hospital settings and is independently associated
with a substantial increase in medical costs. Optimal use
of existing antimicrobial agents through education of
health professionals, antibiotic policies (including anti-
biotic stewardship), implementation of infection control
measures (e.g., hand hygiene, environmental cleaning,
active screening cultures and isolation), and reducing
the length of patient stay should be the strategies aimed
at preventing the emergence and spread of antibiotic
resistance in order to limit their adverse consequences,
including their economic cost.
Abbreviations
CI: Confidence interval; DRG: Diagnosis-Related-Groups; HIV: Human
Immunodeficiency Virus; ICU: intensive care unit; LOS: length of hospital stay;
MDRPA: multi-drug resistant P. aeruginosa; PA: Pseudomona aeruginosa.
Competing interests
The authors declare that they have no competing interests.
Acknowledgements
We thank the members of the Infection Control Program from Hospital del
Mar, Barcelona (Spain).
Author details
1Health Services Evaluation and Clinical Epidemiology Department, Hospital
del Mar-IMIM, Barcelona, Spain. 2Preventive Medicine and Public Health
Training Unit IMAS-UPF-ASPB, Barcelona, Spain. 3CIBER de Epidemiología y
Salud Pública (CIBERESP), Barcelona, Spain. 4Ciencias de la Salut, Universitat
Oberta de Catalunya, Barcelona, Spain. 5Departament de Pediatria,
Ginecología i Salut Pública, UAB, Barcelona, Spain. 6Department of
Microbiology, Laboratorio de Referencia de Catalunya, Barcelona, Spain.
7Pharmacy Service, Hospital del Mar-IMAS, Barcelona, Spain. 8Internal
Medicine and Infectious Diseases Department, Hospital del Mar, Barcelona,
Spain.
Authors’ contributions
EM carried out the statistical analyses and drafted the manuscript. MC and
FB contributed statistical advice for analyses. MS, SG were involved in data
collection and laboratory analysis. FC, MS, MR and XC participated in the
design and coordination of the study and helped to draft the manuscript.
JPH and MMM helped to draft the manuscript. All authors read and
approved the final manuscript.Received: 15 October 2010 Accepted: 23 May 2012
Published: 23 May 2012
References
1. Acar JF: Consequences of bacterial resistance to antibiotics in medical
practice. Clin Infect Dis 1997, 24:S17–S18.
2. Cohen ML: Epidemiology of drug resistance: implications for a post-
antimicrobial era. Science 1992, 257:1050–1055.
3. Nicasio AM, Kuti JL, Nicolau DP: The current state of multidrug-resistant
gram-negative bacilli in North America. Pharmacotherapy 2008,
28:235–249.
4. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Barlett JG:
Antimicrobial Availability Task Force of the Infectious Diseases Society of
America: Bad bugs need drugs: an update on the development pipeline
from the Antimicrobial Availability Task Force of the Infectious Diseases
Society of America. Clin Infect Dis 2006, 42:657–668.
5. Souli M, Galani I, Giamarellou H: Emergence of extensively drug-resistant
and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill 2008,
13(47):1–11. pii: 19045.
6. Hidron AI, Edwards JR, Patel J, Horan TC, Sievert DM, Pollock DA, Fridkin SK:
NHSN annual update: antimicrobial-resistant pathogens associated with
healthcare-associated infections: annual summary of data reported to
the National Healthcare Safety Network at the centers for disease
control and prevention, 2006–2007. Infect Control Hosp Epidemiol 2008,
29:996–1011.
7. Tacconelli E, Tumbarello M, Bertagnolio S, Citton R, Spanu T, Fadda G,
Cauda R: Multidrug-resistant Pseudomonas aeruginosa bloodstream
infections: analysis of trends in prevalence and epidemiology. Emerg
Infect Dis 2002, 8:220–221.
8. Montero M, Sala M, Riu M, Belvis F, Salvado M, Grau S, Horcajada JP,
Alvarez-Lerma F, Terradas R, Orozco-Levi M, et al: Risk factors for
multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of
antibiotic use in a double case–control study. Eur J Clin Microbiol Infect Dis
2010, 29:335–339.
9. Carmeli Y, Troillet N, Karchmer AW, Samore MH: Pseudomonas aeruginosa:
health and economic impact of antibiotic resistance and emergence of
resistance. Arch Intern Med 1999, 159:1127–1132.
10. Montero M, Domínguez M, Orozco-Levi M, Salvadó M, Knobel H: Mortality
of COPD patients infected with multi-resistant Pseudomonas aeruginosa:
a case and control study. Infection 2009, 37:16–19.
11. Harris A, Torres-Viera C, Venkataraman L, DeGirolami P, Samore M, Carmeli Y:
Epidemiology and clinical outcomes of patient with multiresistant
Pseudomonas aeruginosa. Clin Infect Dis 1999, 28:1128–1133.
12. Bou R, Lorente L, Aguilar A, Perpiñán J, Ramos P, Peris M, Gonzalez D:
Hospital economic impact of an outbreak of Pseudomonas aeruginosa
infections. J Hosp Infect 2009, 71:138–142.
13. Cosgrove SE: The relationship between antimicrobial resistance and
patient outcomes: mortality, length of hospital stay, and health care
costs. Clin Infect Dis 2006, 42:S82–S89.
14. Montero M, Horcajada JP, Sorlí L, Alvarez-Lerma F, Grau S, Riu M, Sala M,
Knobel H: Effectiveness and safety of colistin for the treatment of
multidrug-resistant Pseudomonas aeruginosa infections. Infection 2009,
37:461–465.
15. All Patient Refined Diagnosis Related Groups (APR-DRGs): Methodology
Overview. Wallingford, CT: 3M Health Information Systems; 1998.
16. Chandler IR, Fetter RB, Newbold RC: Cost accounting and budgeting.
In DRGs. Their design and development. Edited by Fetter RB, Brand DA,
Gamache D. Ann Arbor: Michigan: Health Administration Press; 1991.
17. Cots F, Castells X, Mercadé L, Torre P, Riu M: Risk adjustment: beyond
patient classification systems. Gac Sanit 2001, 15:423–431.
18. Ghaffari S, Doran C, Wilson A, Aisbett C, Jackson T: Investigating DRG cost
weights for hospitals in middle income countries. Int J Health Plann
Manage 2009, 24:251–264.
19. Young DW, Pearlman LK: Managing the stages of hospital cost
accounting. Healthc Financ Manage 1993, 47:58–80.
20. Udpa S: Activity-based costing for hospitals. Health Care Manag Rev 1996,
21:83–96.
21. Falagas ME, Koletsi PK, Bliziotis IA: The diversity of definitions of
multidrug-resistant (MDR) and pandrug-resistant (PDR) Acinetobacter
baumannii and Pseudomonas aeruginosa. J Med Microbiol 2006,
55:1615–1617.
Morales et al. BMC Health Services Research 2012, 12:122 Page 8 of 8
http://www.biomedcentral.com/1472-6963/12/12222. Lautenbach E, Weiner MG, Nachamkin I, Bilker WB, Sheridan A, Fishman NO:
Imipenem resistance among Pseudomonas aeruginosa isolates: risk
factors for infection and impact of resistance on clinical and economic
outcomes. Infect Control Hosp Epidemiol 2006, 27:893–900.
23. Beyersmann J, Kneib T, Schumacher M, Gastmeier P: Nosocomial infection,
length of stay, and time-dependent bias. Infect Control Hosp Epidemiol
2009, 30:273–276.
24. Roberts RR, Scott RD 2nd, Hota B, Kampe LM, Abbasi F, Schabowski S,
Ahmad I, Ciavarella GG, Cordell R, Solomon SL, Hagtvedt R, Weinstein RA:
Costs attributable to healthcare-acquired infection in hospitalized adults
and a comparison of economic methods. Med Care 2010, 48:1026–1035.
doi:10.1186/1472-6963-12-122
Cite this article as: Morales et al.: Hospital costs of nosocomial multi-
drug resistant Pseudomonas aeruginosa acquisition. BMC Health Services
Research 2012 12:122.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
